Roivant Shares Rally 19.4% on Brepocitinib’s 22.3% Trial Gain and NDA Filing
Roivant shares jumped 19.4% week-over-week to an all-time high after Priovant’s Brepocitinib trial delivered a 22.3% CSAMI-A score improvement versus 0.7% for placebo. The company filed an NDA for dermatomyositis, plans a non-infectious uveitis trial in H2 2026 and reported Q3 net loss of $265.9M versus a $169M profit year-ago.
1. Stock Performance
Roivant shares surged 19.4% week-over-week, closing at an all-time high after upbeat pipeline updates fueled investor buying, including a 22.14% intraday gain on Friday.
2. Pipeline Progress
Priovant’s Phase 2 trial of Brepocitinib in cutaneous sarcoidosis achieved a 22.3% improvement in CSAMI-A score after 16 weeks versus 0.7% for placebo, leading to an NDA submission for dermatomyositis. A third trial for non-infectious uveitis is slated for H2 2026, while Immunovant and Pulmovant advance therapies in autoimmune and pulmonary hypertension indications.
3. Financial Results
The company reported a Q3 net loss of $265.9 million, reversing a $169 million profit in the same period a year earlier, and widened nine-month losses to $602.8 million versus prior nine-month income of $34.5 million, prompting investor caution despite pipeline momentum.